Kezdőlap・Részvénylista・Roivant Sciences Ltd

Roivant Sciences Ltd

Lezárt

SzektorEgészségügy

34.58 0.26

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

34.24

Maximum

35.5

Fő mutatók
By Trading Economics
Bevétel	669M 356M
Értékesítés	521K 2.5M
Profit margin	14,116.825
Munkavállalók	721
EBITDA	744M 455M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+5.84% upside

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	3.9B 24B
Előző nyitás	34.32
Előző zárás	34.58

Hangulat hírek alapján

By Acuity

50%

175 / 340 Rangsor szerint Healthcare

Roivant Sciences Ltd Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 4. 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

2026. aug. 3. 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

2026. júl. 31. 20:02 UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

2026. júl. 30. 23:46 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting a modest gain since Thursday's close. The stock fluctuated within a narrow range.

2026. júl. 29. 23:02 UTC

Roivant Sciences Ltd shares are lower in after-market hours amid broader market concerns and unusual volatility, with no specific company news identified.

2026. júl. 28. 23:06 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news to explain the movement.

2026. júl. 24. 18:46 UTC

Roivant Sciences Ltd shares are trading higher, reflecting broader market dynamics amid a rebound in some sectors following a significant decline in oil prices.

2026. júl. 23. 20:06 UTC

Roivant Sciences Ltd is higher during Thursday's session, despite pulling back from an earlier session high. No specific news was identified for the movement.

2026. júl. 22. 22:26 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market volatility.

2026. júl. 21. 22:21 UTC

Roivant Sciences Ltd shares are lower in after-market hours, despite a broader market rebound following positive earnings from companies like General Motors and 3M.

2026. júl. 20. 16:36 UTC

Roivant Sciences Ltd. shares are lower today amid ongoing Middle East conflict affecting market sentiment and fluctuations in Brent crude prices.

Társak összehasonlítása

Árváltozás

Roivant Sciences Ltd Előrejelzés

Célár

By TipRanks

5.84% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 36.61 USD 5.84%

Magas 42 USD

Alacsony 29.29 USD

7 Wall Street elemző 12 hónapos célárain alapulva a(z)Roivant Sciences Ltd termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

7 ratings

Vétel

Tartás

Eladás

7 Wall Street elemző célárain alapulva a(z)Roivant Sciences Ltd termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

175 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.